Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Becton Dickinson and Company(BDX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BDX
11/06/2026: BDX (3-star) is a STRONG-BUY. BUY for 12 days. Simulated Profits (5.72%). Updated daily EoD!
Becton Dickinson is a global medical technology company that provides a wide range of essential diagnostic and medication management products. The company is known for its durable and stable business model, bolstered by a massive installed base of equipment that drives recurring revenue. Its primary investment story centers on leveraging this footprint to expand into high-growth diagnostic and digital health segments. While it maintains a leading market position, the company faces risks from intense healthcare pricing pressures and the integration of its complex product portfolio. It remains a suitable choice for value and dividend-focused investors seeking exposure to the stable, defensive medical device sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers reliable, steady growth rather than explosive expansion. |
| Momentum investor | Mixed fit | Price performance is typically driven by long-term fundamentals rather than short-term rapid upturns. |
| Value investor | Strong fit | The stock often trades at reasonable valuation multiples relative to its stable earnings power. |
| Dividend investor | Strong fit | A long history of consecutive dividend increases makes it a staple for income-focused portfolios. |
| Low-risk investor | Strong fit | The essential nature of medical supplies provides a defensive cushion against economic downturns. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | The stock is generally less volatile than the broader market due to its defensive healthcare nature. |
| Valuation risk | Medium | Market pricing can sometimes lead to premium valuations that temper potential upside. |
| Competition risk (Medtech consolidation) | Medium / high | Aggressive moves by competitors in the diagnostic space can threaten market share in key segments. |
| Business quality | Strong | The company's deep integration into hospital workflows provides a high-quality, durable franchise. |
| Dividend income | Strong | Commitment to decades of dividend growth ensures consistent, reliable income for shareholders. |
| Execution risk | Medium | Successfully integrating future acquisitions and managing complex supply chains is essential for long-term margins. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 13.72% | Avg. Invested days 45 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 57.71B USD | Price to earnings Ratio 41.87 | 1Y Target Price 195.57 |
Price to earnings Ratio 41.87 | 1Y Target Price 195.57 | ||
Volume (30-day avg) 1.8M shares | Beta 0.28 | 52 Weeks Range 134.94 - 214.88 | Updated Date 11/08/2026 |
52 Weeks Range 134.94 - 214.88 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.06 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Medication Delivery Solutions | Needles, syringes, and infusion technology. | The foundation of the business providing recurring revenue through daily hospital usage. |
| Interventional Surgery | Specialized instruments for vascular and urology procedures. | High-margin products that capitalize on complex medical procedures. |
| Geography | Global sales across North America, EMEA, and Asia. | Well-diversified international presence reduces reliance on any single economy. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When Before Market | Estimate 4.06 | Actual 4.15 |
Profitability
Profit Margin 5.89% | Operating Margin (TTM) 21.63% |
Management Effectiveness
Return on Assets (TTM) 3.59% | Return on Equity (TTM) 5.66% |
Valuation
Trailing PE 41.87 | Forward PE 15.92 | Enterprise Value 73.33B | Price to Sales(TTM) 2.97 |
Enterprise Value 73.33B | Price to Sales(TTM) 2.97 | ||
Enterprise Value to Revenue 3.77 | Enterprise Value to EBITDA 15.92 | Shares Outstanding 272.39M | Shares Floating 272.22M |
Shares Outstanding 272.39M | Shares Floating 272.22M | ||
Percent Insiders 0.43 | Percent Institutions 99.1 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.